Gilead's Late-Stage R&D Misfire Gives Respite To Competing Myelofibrosis Therapies

The JAK inhibitor momelotinib meets some endpoints but misses others in two late-stage clinical studies in myelofibrosis, a condition that has proved recalcitrant to various new approaches, leaving Incyte/Novartis’s marketed product ruxolitinib as one of the few successes.